TCN 238
- CAS No.
- 125404-04-8
- Chemical Name:
- TCN 238
- Synonyms
- TCN 238;Lu AF32615;TCN 238; TCN-238;TCN238, 10 mM in DMSO;4-Styryl-pyrimidin-2-ylamine;(E)-4-(2-Phenylethenyl)-2-pyriMidinaMine;2-PyriMidinaMine, 4-(2-phenylethenyl)-, (E)-;2-PyriMidinaMine, 4-(2-phenylethenyl)-, (E)- (9CI);inhibit,TCN-238,mGluR,TCN238,Metabotropic glutamate receptors,Inhibitor
- CBNumber:
- CB02546791
- Molecular Formula:
- C12H11N3
- Molecular Weight:
- 197.24
- MDL Number:
- MOL File:
- 125404-04-8.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Boiling point | 414.883±43.00 °C(Press: 760.00 Torr)(predicted) |
|---|---|
| Density | 1.222±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) |
| storage temp. | Store at -20°C |
| solubility | DMF: 25 mg/ml; DMSO: 25 mg/ml; DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml; Ethanol: 5 mg/ml |
| form | Powder |
| pka | 4.055±0.10(predicted) |
| color | White to off-white |
TCN 238 price More Price(41)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 11994 | TCN 238 ≥98% | 125404-04-8 | 5mg | $107 | 2026-04-30 | Buy |
| Cayman Chemical | 11994 | TCN 238 ≥98% | 125404-04-8 | 10mg | $203 | 2026-04-30 | Buy |
| Cayman Chemical | 11994 | TCN 238 ≥98% | 125404-04-8 | 25mg | $477 | 2026-04-30 | Buy |
| Usbiological | 256867 | TCN 238 Asreported | 125404-04-8 | 10mg | $446 | 2026-06-03 | Buy |
| Usbiological | 256867 | TCN 238 Asreported | 125404-04-8 | 50mg | $1197 | 2026-06-03 | Buy |
TCN 238 Chemical Properties, Uses, Production
Uses
TCN 238 allosteric modulator of the mGlu4 receptor. TCN 238 may be useful in the treatment of motor dysfunction and in the treatment of Parkinson’s disease. TCN 238 is orally bioavailable.
Uses
TCN 238 allosteric modulator of the mGlu4 receptor (1). TCN 238 may be useful in the treatment of motor dysfunction and in the treatment of Parkinson’s disease. TCN 238 is orally bioavailable.
in vivo
TCN238 is highly CNS penetrant with a concentration of 33.8 μM in the brain. The plasma protein binding in rats is measured as 90% bound. The metabolic stability of TCN238 is assessed in rat and human microsomes and found to be 62% and 83% hepatic blood flow. The limited stability translated into a high in vivo clearance in rats of 75 mL/min/kg and TCN238 has a moderate volume of distribution (2.7 L/kg) with a short mean residence time (0.6 h) when dosed at 2 mg/kg via intravenous injection. TCN238 is orally bioavailable and 30 min following administration of a30 mg/kg dose, the plasma concentration is found to be 11.6 μM[1]. TCN 238 does not affect the performance of the learned task. However, the expression level of GRM4 in the hippocampus is reliable down-regulated five days after treatment with TCN 238. In addition, the expression level of GABRA1, encoding GABAA α-subunit is downregulated five days after the treatment in the frontal cortex[2].
IC 50
mGlu4 Receptor: 1 μM (EC50)
TCN 238 Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| J & K SCIENTIFIC LTD. | 18210857532 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| Chemsky (shanghai) International Co.,Ltd | 021-50135380 | shchemsky@sina.com | China | 15350 | 60 |
| Hangzhou Sage Chemical Co., Ltd. | +86057186818502 13588463833 | info@sagechem.com | China | 10265 | 58 |
| SynAsst Chemical. | 021-60343070 | China | 12731 | 55 | |
| MedChemexpress LLC | 021-58955995 | sales@medchemexpress.cn | United States | 4853 | 58 |
| Nanjing Chalf-Pharm Technology Co., Ltd. | 025-57018978 18251899859 | sales@chalf-pharm.com | China | 5855 | 50 |
| EMMX Biotechnology LLC | 888-539-0666 | info@emmx.com | United States | 8435 | 60 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9799 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Zhengzhou Ruke Biological Co., Ltd. | 15981811963 | 1410472904@qq.com | China | 5824 | 58 |
